Literature DB >> 5641777

Obstructive disease of the airways in cystic fibrosis.

R B Mellins, O R Levin, R H Ingram, A P Fishman.   

Abstract

Entities:  

Mesh：

Year:  1968        PMID： 5641777

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  9 in total

1.  Maximal expiratory flow at FRC (V'maxFRC): Methods of selection and differences in reported values.

Authors:  Anastassios C Koumbourlis; Xin C Chen; J Sunil Rao; Mark D Schluchter; Kirk Easley; Andrew A Colin; Peter Hiatt; Meyer Kattan; Kevin McCarthy; Robert B Mellins; Hannah Peavy; Arnold C G Platzker; Suzanne Steinbach; Andrew Ting; Michael D Weisner; Mary Ellen B Wohl
Journal:  Pediatr Pulmonol       Date:  2004-04

Review 2.  Pathogenesis and management of lung disease in cystic fibrosis.

Authors:  M S Zach
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

3.  Lung function in infants with cystic fibrosis.

Authors:  C S Beardsmore; E Bar-Yishay; C Maayan; Y Yahav; D Katznelson; S Godfrey
Journal:  Thorax       Date:  1988-07       Impact factor: 9.139

4.  Ventilatory function in infants with cystic fibrosis. Physiological assessment of halation therapy.

Authors:  P D Phelan; M Gracey; H E Williams; C M Anderson
Journal:  Arch Dis Child       Date:  1969-06       Impact factor: 3.791

5.  Pulmonary function and response to exercise in cystic fibrosis.

Authors:  S Godfrey; M Mearns
Journal:  Arch Dis Child       Date:  1971-04       Impact factor: 3.791

6.  Atopy and bronchial reactivity in older patients with cystic fibrosis.

Authors:  M J Tobin; O Maguire; D Reen; E Tempany; M X Fitzgerald
Journal:  Thorax       Date:  1980-11       Impact factor: 9.139

7.  The effect of isoproterenol on airway obstruction in cystic fibrosis.

Authors:  E A Featherby; T R Weng; H Levison
Journal:  Can Med Assoc J       Date:  1970-04-25       Impact factor: 8.262

8.  Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis.

Authors:  M Kattan; A Mansell; H Levison; M Corey; I R Krastins
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

9.  Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.

Authors:  R Demnati; M C Michoud; A Jeanneret-Grosjean; H Ong; P Du Souich
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.